EUCTR2008-004207-63-ES进行中（未招募）1 期
Ensayo en doble ciego y controlado con placebo, de 12 semanas de duración, de LY2428757 en pacientes con diabetes mellitus de tipo 2.A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus
Eli Lilly and Company, Indianapolis0 个研究点目标入组 300 人开始时间: 2008年12月15日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Have T2DM for at least 6 months before entering the trial based on the disease diagnostic criteria (World Health Organization [WHO]) classification (see Protocol Attachment GECD.3).
- •- Are currently being treated with diet and exercise therapy consistent with the local standards of medical care, in the opinion of the investigator.
- •- Patients may be treated with diet and exercise alone or in combination with a stable dose, at least 1000 mg/day, of metformin for at least 2 months before Visit 1.
- •- Have an HbA1c value of 7% to 10% , inclusive, at Visit 1 and a fasting glucose ?15 mmol/L (270 mg/dL) at Visit 2.
- •- Men or women who are between the ages of 18 to 70 years, inclusive.
- •- Women of child-bearing potential must test negative for pregnancy at the time of Visit 1 and agree to abstain from heterosexual intercourse for the duration of the study, or use 2 effective forms of birth control during the study, including at least 1 of the following: tubal ligation (sterilization), partner's vasectomy, intrauterine device, or hormonal treatment (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring). Other forms of contraception that can be combined with 1 of the above are male latex condom with or without spermicide, diaphragm with spermicide, cervical cap with spermicide, or vaginal sponge.
- •- Have a body mass index (BMI) between 25 and 40 kg/m2, inclusive at Visit 1.
- •- Weight stable (±5 kg) during the 3 months before Visit 1 (by patient self-report).
- •- In the investigator?s opinion, are well motivated, capable, and willing to
- •?perform self monitoring of blood glucose (SMBG)
- •?complete study diary/ies, as required for this protocol
- •?are receptive to continuing their prestudy diet, activity levels, and follow simple dietary advice as appropriate
- •?comply with the required study and dosing visits.
- •- Have given written informed consent to participate in this study in accordance with local regulations and the Ethical Review Board (ERB) governing the study site.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Use of insulin or any antidiabetic agent other than metformin during the 2 months before Visit (V) 1.
- •- In the opinion of the investigator, have a gastrointestinal disease that significantly impacts gastric empting or motility or have undergone bariatric surgery.
- •- Have had more than 1 episode of severe hypoglycemia, as defined in the Abbreviation and Definitions section of this protocol, within 6 months before entry into the study, or is currently diagnosed with having hypoglycemia unawareness.
- •- Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the past 6 months.
- •-Are currently taking prescription or over-the-counter medications to
- •promote weight loss.
- •- Have a history of acute or chronic pancreatitis or elevation of serum lipase (greater than 2 times the upper limit of normal).
- •-Women who are breastfeeding.
- •- In the last 2 years, have known or suspected cardiac autonomic neuropathy, based on clinical signs, symptoms, or appropriate diagnostic testing.
- •- Have cardiac disease with functional status that is NYHA Class II, III, or IV or a history of myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure in the past 6 months.
- •- Have poorly controlled hypertension at V1 or V2, malignant hypertension, renal artery stenosis, and/or evidence of labile blood pressure including symptomatic postural hypotension. Doses of antihypertensive medications must be stable for 30 days before randomization.
- •-Have resting tachycardia at V1 or V2 or a history of a supraventricular tachycardia, ventricular tachycardia, or other cardiac arrhythmia that, in the opinion of the investigator, may preclude the patient from participating in the protocol.
- •- Have an EKG considered by the investigator to be outside of normal limits and relevant for interpretation or indicating cardiac disease at V1. The following conduction abnormalities may confound QTc analysis and should be avoided: second- or third-degree atrioventricular block, delayed intraventricular conduction with QRS >120 msec, left bundle branch block, complete right bundle branch block, or Wolff-Parkinson-White. A QTc interval greater than450 msec in men and greater than 470 in women or a PR interval more than 220 msec are specifically excluded.
- •- Personal or family history of long QT syndrome, family history of sudden death in a first-degree relative before age 40, or personal history of unexplained syncope within the last year. Use of prescription or over-the-counter medications known to prolong the QT or QTc interval.
- •- Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or an alanine transaminase or aspartate aminotransferase levels >2.5 times the upper limit of the reference range at V1.
- •- Have a serum creatinine >2 mg/dL or, in patients being treated with metformin, a serum creatinine above what is approved in the metformin product labeling in the respective country.
- •- Have severe hypertriglyceridemia at V1. If taking lipid-lowering agents, doses of these medications must be stable for 30 days before randomization.
- •- Evidence of hypothyroidism or hyperthyroidism based on clinical evaluation and/or an abnormal thyroid-stimulating hormone result at V1 and which, in the opinion of the investigator, would confound data interpretation or pose a risk to patient safety. Subjects
研究者
相似试验
进行中（未招募）
不适用
Estudio doble ciego, controlado con placebo sobre la eficacia y tolerancia de V0251 1g, 2g y 4g en neuritis vestibularA double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis.EUCTR2007-005054-23-ESPIERRE FABRE MEDICAMENT - IRPF120
进行中（未招募）
1 期
Ensayo doble ciego, controlado con placebo, en grupos paralelos, prueba conceptual del ensayo para valorar la tolerabilidad, seguridad y eficacia de rotigotina en spray nasal para el tratamiento agudo del periodo sintomático en pacientes con enfermedad de parkinson idiopática en estado avanzado.Enfermedad de Parkinson idiopática, en estado avanzado.MedDRA version: 8.1Level: LLTClassification code 10061536EUCTR2005-004290-19-ESSchwarz Biosciences GmbH100
进行中（未招募）
1 期
Ensayo en doble ciego, controlado con placebo, intrapaciente, para evaluar la eficacia de Juvista (avotermina) junto con cirugía correctora de la cicatriz para la mejoría de cicatrices deformantes.A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars. - Juvista in scar revision surgery of disfiguring scarsEUCTR2008-002124-28-ESRenovo Ltd350
进行中（未招募）
不适用
Estudio doble ciego, controlado con placebo, con aumento gradual de dosis, en grupos paralelos para evaluar la eficacia y la seguridad de E2007 (perampanel) administrado como terapia adyuvante en pacientes con crisis parciales refractariasA Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial SeizureEUCTR2007-006169-33-ESEisai Ltd816
进行中（未招募）
1 期
Estudio doble ciego, controlado frente a placebo, de grupos paralelos, a dosis fija, para evaluar la eficacia y la seguridad del tratamiento con Armodafinilo (150 y 200 mg/día) como Terapia Adjunta en Adultos con Depresión Mayor Asociada a Trastorno Bipolar tipoDepresión Mayor asociada con Trastorno Bipolar IEUCTR2009-016634-27-ESCephalon, Inc.400